

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_83144
Title of the Manuscript:	Formulation and Characterisation of RGD-FBG based Nanoscaffolds as Novel Anti-Cancer drug delivery system.
Type of the Article	

### General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

## Review Form 1.6

### PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<p>1- It is suggested that the title of paper corrected to : <b>Formulation and Characterisation of RGD-FBG based Nanoscaffolds as novel anti-cancer drug delivery system.</b></p> <p>2- In a separate section in the introduction, <b><i>Everolimus</i> should be fully compared with other drugs used as anti-cancer materials, and the advantages of this drug should be expressed in relation to other materials. Also the chemical structure of this drug must be drawn.</b></p> <p>3- <b>Draw Chemical structure of RGD-FBG material, and report the reasons for selecting them.</b></p> <p>4- <b>Specify the phrase “ Figure 1” in the text of the article.</b></p> <p>5- <b>Increase the quality of Figure 2, also mention its scale in the caption of the figure and mark it inside the figure with a red line .</b></p> <p>6- <b>Discuss about releasing behavior of the <i>Everolimus</i> more comprehensively. (Burst release? why?)</b></p> <p>7- <b>Add a diagram in the releasing section; (amount of released drugs versus time) and discuss about them carefully (section 3-3-3).</b></p> <p>8- <b>In section 3-3-3, the duration time of drug releasing of scaffolds should be compared with scientific reasons.</b></p> <p>7- <b>Check the whole of article grammatically.</b></p> <p>8- <b>Why there is not any estimation about the fibrous structure of the scaffolds (with SEM figures)?</b></p> <p>9- <b>Can you give the SEM or FE-SEM that shows the nano-scale drug particles in a 10000x scale?</b></p>	<p>1. Agreed and Revised.</p> <p>2. Agreed, Revised, highlighted in manuscript.</p> <p>3. Agreed and stated the reasons in separate section 1.2</p> <p>4. Agreed and specified.</p> <p>5. Mentioned with the range and caption.</p> <p>6. Mentioned the drug release along with the graphical representation.</p> <p>7. Mentioned in graphical form.</p> <p>8. Mentioned in graphical form.</p> <p>9. Checked.</p> <p>10. TEM study was performed to elucidate the unprecedented structure of nanoscaffolds. SEM study was not performed for the formulation.</p> <p>11. The authors reply to the received comments is mentioned in the manuscript section as part of justification.</p>
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments		

### PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	No ethical issues involved.